Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Mendel Biotechnology

Request full access

Plant biotechnology company that develops genetic and chemical solutions for a range of agricultural markets

Hayward, United StatesFounded 1997Biotech & Life Sciences

About Mendel Biotechnology

Founded in 1997, Mendel Biotechnology, Inc. operates as a plant biotechnology company from its base in the San Francisco Bay Area, California. The company was co-founded by Jonathan Jones and Dr. Brian Staskawicz. Staskawicz, a renowned expert in plant biology and a professor at the University of California, Berkeley, has been a member of the board of directors since the company's inception. The firm has focused on researching the control of plant gene regulation, establishing a significant intellectual property portfolio centered on transcription factor-based technologies designed to enhance crop plant traits.

The company's business model revolves around commercializing its proprietary technology through strategic partnerships and licensing agreements with major agricultural companies. Key collaborators have included Monsanto, BP, and Bayer CropScience. The long-term partnership with Monsanto, initiated in 1997, granted the multinational corporation exclusive, royalty-bearing licenses to Mendel's technology for use in large-acreage crops. Successful commercialization of products incorporating Mendel's technology, such as advanced soybean yield traits, results in milestone and royalty payments to the company. A strategic collaboration with BP, established in 2007, focused on developing and commercializing seeds for dedicated energy crops like Miscanthus and switchgrass for the second-generation biofuels industry. The company also engaged in research partnerships with Bayer CropScience to develop chemical products that regulate plant stress tolerance.

In December 2014, Mendel Biotechnology sold its research and development operations and certain assets to a subsidiary of Koch Agronomic Services. Following this transaction, Mendel Biotechnology transitioned to operate as an IP holding company, managing its extensive portfolio of patents and know-how related to genetic traits. The company continues to offer new licensing opportunities for its patented technologies. The R&D operations acquired by Koch were used to form a new business unit, initially called Koch Biological Solutions and later Mendel Biological Solutions, which was subsequently spun out and merged with another company in 2019.

Source: Dealroom company data

At a glance

Status
Acquired
Founded
1997
Headquarters
Hayward, United States
Open positions
None listed
Dealroom signal
50.5/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Links
Website

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Dec 2014 $0 — Koch Agronomic Services —
SERIES F✓Equity / VC Nov 2011 $12M $47M Undisclosed —
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Mendel Biotechnology website traffic

Latest recorded traffic for Mendel Biotechnology is 230 monthly website visits, down 96.8% over the last three months.

Latest monthly visits230 3-month web change-96.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Mendel Biotechnology in the Hayward ecosystem

Live from Dealroom

The Mendel Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later2 investors entered at this stage

  • Capricorn Partners
  • Monsanto

Other known investors2 additional known investors

  • Koch Agronomic Services
  • University of California, Berkeley
Team profiled 13 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Hayward HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Mendel Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Mendel Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.